Dysbiosis and Gut Microbiota Modulation in Systemic Sclerosis
Nenhuma Miniatura disponível
Data
2022-03-01
Autores
Lemos, Maria Paula Calil
Zucoloto, Talita Graminha
Oliveira, Maria Carolina
De Oliveira, Gislane Lelis Vilela [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Gastrointestinal (GI) involvement is an early manifestation in systemic sclerosis (SSc), affecting more than 90% of patients, and severe GI disease is a marker of poor prognosis and mortality. Recent studies have hypothesized that alterations of the intestinal microbiota, known as dysbiosis, may represent 1 of the possible environmental factors influencing SSc disease status. In addition, specific microorganisms may be associated with SSc pathogenesis, progression, and GI manifestations. Therapeutic approaches aiming to modulate the intestinal microbiota have emerged, as alternatives to treat GI symptoms, and dietary interventions, probiotic administration, and fecal microbiota transplantation are potential therapies for SSc patients. However, given the complexity and variability of pathogenesis and clinical manifestations in SSc, these therapies need to be combined with additional interventions that target other disease components. Here, we summarize studies addressing intestinal dysbiosis in SSc and discuss the potential of microbiota modulators to treat SSc-related GI disorders.
Descrição
Palavras-chave
dietary interventions, fecal microbiota transplantation, gastrointestinal manifestations, intestinal dysbiosis, microbiota, probiotics, systemic sclerosis
Como citar
Journal of Clinical Rheumatology, v. 28, n. 2, p. 568-573, 2022.